Boston Scientific — Oct 23, 2024 release

BOSTON SCIENTIFIC CORPORATION Q4 and FY 2024 GUIDANCE RECONCILIATIONS (Unaudited) Net Sales Q4 2024 Estimate (Low) (High) Full Year 2024 Estimate Reported growth 16.5   % 18.5   % ~16.5% Impact of foreign currency fluctuations (0.5) % (0.5) % ~0.5% Operational growth 16.0   % 18.0   % ~17.0% Impact of acquisitions/divestitures (2.0) % (2.0) % ~(2.0)% Organic growth 14.0   % 16.0   % ~15.0% Earnings per Share Q4 2024 Estimate Full Year 2024 Estimate (Low) (High) (Low) (High) GAAP results $ 0.41   $ 0.43   $ 1.28   $ 1.30   Amortization expense 0.12  0.12  0.48  0.48  Intangible asset impairment charges —  —  0.16  0.16  Acquisition/divestiture-related net charges (credits) 0.03  0.03  0.24  0.24  Restructuring and restructuring-related net charges (credits) 0.04  0.04  0.13  0.13  Other adjustments 0.04  0.04  0.15  0.15  Adjusted results $ 0.64   $ 0.66   $ 2.45   $ 2.47   Use of Non-GAAP Financial Measures To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance